Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
The present post hoc analyses generate hypotheses regarding the interaction between menopausal status, tamoxifen, and everolimus in patients with high-risk, ER-positive, human epidermal growth factor receptor type 2-negative early breast cancer. They suggest that tamoxifen alone is an underpowered endocrine treatment in high-risk premenopausal patients.
Authors
- Audrey Mailliez (ORCID: https://orcid.org/0000-0002-0475-8631)
- Fabrice André (ORCID: https://orcid.org/0000-0001-5795-8357)
- Laure Kaluzinski
- Judith M. Bliss (ORCID: https://orcid.org/0000-0001-7957-7424)
- Murray Brunt
- Sylvie Giacchetti (ORCID: https://orcid.org/0000-0001-8079-2930)
- A-C. Hardy-Bessard
- S. Chabaud
- Melissa Martínez (ORCID: https://orcid.org/0000-0003-2683-1243)
- Éric Legouffe
- Djelila Allouache (ORCID: https://orcid.org/0009-0009-3693-3199)
- P. Cottu
- Jean‐Christophe Grenier (ORCID: https://orcid.org/0000-0001-7937-5160)
- Mathilde Saint‐Ghislain (ORCID: https://orcid.org/0000-0001-9432-6762)
- T. Bachelot
- F. Dalenc
- D. Cameron (ORCID: https://orcid.org/0000-0001-6097-2256)
- Philippe Barthélémy (ORCID: https://orcid.org/0009-0006-3868-186X)
- J.-L. Canon
- Jérôme Lemonnier
- M-A Mouret-Reynier
Institutions
- Institute of Cancer Research (GB)
- Royal Stoke University Hospital (GB)
- Institut Gustave Roussy (FR)
- Edinburgh Cancer Research (GB)
- Institut de Cancérologie Strasbourg (FR)
- Centre Léon Bérard (FR)
- Centre François Baclesse (FR)
- Centre Jean Perrin (FR)
- Centre Oscar Lambret (FR)
- Clinique Pasteur (FR)
- UniCancer Group (FR)
- Hôpital Saint-Louis (FR)
- Centre Hospitalier Public du Cotentin (FR)
- Grand Charleroi Hospital (BE)
- Institut Sainte Catherine (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105050
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00